Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple SclerosisEline M. E. Coerver, Eva Strijbis, Jop Mostert et al.|JAMA Neurology|2024Cited by 29
Association of Arachidonic Acid–Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple SclerosisJelle Y. Broos, Gijs Kooij, Menno M. Schoonheim et al.|Neurology|2023Cited by 24
9-HODE associates with thalamic atrophy and predicts white matter damage in multiple sclerosisWing Hee Fung, Gijs Kooij, Helga E. de Vries et al.|Multiple Sclerosis and Related Disorders|2024Cited by 4
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)Wing Hee Fung, Eva Strijbis, Jop Mostert et al.|Journal of Neurology|2025Cited by 4